SCHEMBL6000167

SCHEMBL6000167

CCC(CC)c1ccc(N(Cc2ccc(-c3csc(COc4ccc(C(=O)O)cc4)n3)cc2)C(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.49
PTPN2 P17706 1/20 0.46
ALOX5 P09917 4/20 0.43
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PPARD Q03181 4/20 0.40
PPARA Q07869 2/20 0.40
PTGES O14684 1/20 0.39
BCHE P06276 2/20 0.39
KMT2A Q03164 1/20 0.38
MAPT P10636 2/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP13 P45452 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6000020 0.90 PTPN1 (0.48) PTPN1PTPN2ALOX5PPARDPPARA
SCHEMBL6000958 0.90 PTPN1 (0.44) PTPN1PTPN2ALOX5RAB9AKDM4E
SCHEMBL5999251 0.90 PTPN1 (0.44) PTPN1PTPN2ALOX5RAB9AKDM4E
SCHEMBL6000965 0.90 PTPN1 (0.40) PTPN1PTPN2ALOX5RAB9AKDM4E
SCHEMBL6000472 0.87 PTPN1 (0.41) PTPN1PTPN2ALOX5RAB9AKDM4E
SCHEMBL6000825 0.86 PTPN1 (0.39) PTPN1PTPN2ALOX5RAB9AKDM4E
SCHEMBL6000506 0.85 PTPN2 (0.48) PTPN1PTPN2ALOX5RXRARXRB
SCHEMBL6000165 0.85 HDAC3 (0.39) PTPN1PTPN2ALOX5RAB9AKDM4E
SCHEMBL6000953 0.85 PTPN1 (0.39) PTPN1PTPN2ALOX5RAB9ANPC1
SCHEMBL6000654 0.84 PTPN1 (0.42) PTPN1PTPN2ALOX5RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US claimed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP claimed
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US disclosed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof PTPN11, PTPN1, PTPN3 PTPN1 2/4885PTPN2 11/4885ALOX5 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.